4-(5-trifluoromethyl-pyridin-2-ylsulfanyl)-benzaldehyde | 882985-35-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-(5-trifluoromethyl-pyridin-2-ylsulfanyl)-benzaldehyde
• 英文别名: 4-[5-(trifluoromethyl)pyridin-2-yl]sulfanylbenzaldehyde
• CAS: 882985-35-5
• 化学式: C₁₃H₈F₃NOS
• mdl: MFCD19528727
• 分子量: 283.274
• InChiKey: ZBMMWRJLFLRABX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  55.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  对氟苯甲醛 、 2-巯基-5-(三氟甲基)吡啶 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以87%的产率得到4-(5-trifluoromethyl-pyridin-2-ylsulfanyl)-benzaldehyde
  参考文献：
  名称：

  Arylthiobenzylpiperidine derivatives

  摘要：

  这项发明涉及芳基硫代苯基哌啶衍生物，这些衍生物是MCH1受体的配体。该发明提供了一种包含该发明化合物的治疗有效量和药用载体的药物组合物。该发明还提供了一种通过混合该发明化合物的治疗有效量和药用载体制备的药物组合物。该发明进一步提供了一种制备药物组合物的方法，包括结合该发明化合物的治疗有效量和药用载体。该发明还提供了一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者施用该发明化合物的治疗有效量。该发明还提供了一种治疗患有肥胖症的受试者的方法，包括向受试者施用该发明化合物的治疗有效量。

  公开号：

  US20060079523A1

文献信息

• Arylthiobenzylpiperidine Derivatives
  申请人：Marzabadi Mohammad R.

  公开号：US20080139555A1

  公开（公告）日：2008-06-12

  This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

  本发明涉及芳基硫代苄基哌啶衍生物，其为MCH1受体的配体。本发明提供一种制备药物组合物的方法，包括将本发明化合物的治疗有效量与药学上可接受的载体混合。本发明还提供一种制备药物组合物的方法，包括将本发明化合物的治疗有效量与药学上可接受的载体混合。本发明还提供一种制备药物组合物的方法，包括将本发明化合物的治疗有效量与药学上可接受的载体混合。本发明还提供一种治疗抑郁症和/或焦虑症的方法，包括向患者施用本发明化合物的治疗有效量。本发明还提供一种治疗肥胖症的方法，包括向患者施用本发明化合物的治疗有效量。
• EP1799223A4
  申请人：——

  公开号：EP1799223A4

  公开（公告）日：2008-01-23
• ARYLTHIOBENZYLPIPERIDINE DERIVATES
  申请人：H.Lundbeck A/S

  公开号：EP1799223A2

  公开（公告）日：2007-06-27
• US7329656B2
  申请人：——

  公开号：US7329656B2

  公开（公告）日：2008-02-12
• [EN] ARYLTHIOBENZYLPIPERIDINE DERIVATES<br/>[FR] DERIVES D'ARYLTHIOBENZYLPIPERIDINE
  申请人：LUNDBECK & CO AS H

  公开号：WO2006041635A2

  公开（公告）日：2006-04-20

  This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.